Artelo Biosciences (NASDAQ:ARTL) Stock Rating Lowered by Wall Street Zen

Artelo Biosciences (NASDAQ:ARTL) was downgraded by equities research analysts at Wall Street Zen to a “strong sell” rating in a report released on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Artelo Biosciences in a research note on Friday, March 27th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Artelo Biosciences presently has an average rating of “Reduce” and an average target price of $54.00.

Artelo Biosciences Trading Up 1.0%

Shares of Artelo Biosciences stock opened at $4.03 on Friday. The firm has a fifty day simple moving average of $5.10 and a 200-day simple moving average of $5.91. Artelo Biosciences has a 1-year low of $2.95 and a 1-year high of $85.80. The stock has a market capitalization of $3.79 million, a price-to-earnings ratio of -0.06 and a beta of 0.41.

About Artelo Biosciences

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.